Canada markets closed

Zoetis Inc. (ZTS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
200.33-1.63 (-0.81%)
At close: 04:04PM EST
200.33 0.00 (0.00%)
After hours: 07:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close201.96
Bid197.67 x 900
Ask200.25 x 1000
Day's Range200.28 - 203.71
52 Week Range141.41 - 249.27
Avg. Volume1,780,338
Market Cap94.781B
Beta (5Y Monthly)0.66
PE Ratio (TTM)48.28
EPS (TTM)4.15
Earnings DateFeb. 15, 2022
Forward Dividend & Yield1.30 (0.65%)
Ex-Dividend DateJan. 19, 2022
1y Target Est248.83
  • Motley Fool

    2 Stocks That Could Turn $250,000 Into $1,000,000 By 2032

    Let's look at two excellent companies that could turn $250,000 into $1,000,000 -- that's a compound annual growth rate of 14.87% -- in the next 10 years: Zoetis (NYSE: ZTS) and Spotify (NYSE: SPOT). Zoetis is one of the leading animal health companies in the world. Zoetis boasts 13 products that generate $100 million or more in annual revenue, and its financial results continue to impress.

  • Business Wire

    Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats

    PARSIPPANY, N.J., January 13, 2022--Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia™ to control the pain of osteoarthritis (OA) in cats.

  • Reuters

    New pain relief for cats with osteoarthritis gets U.S. approval

    The U.S. health regulator on Thursday approved Zoetis Inc's once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats. Osteoarthritis breaks down the protective cartilage that cushions the joints, leading to increased friction that causes pain and decreased movement. The drug, Solensia, with the active ingredient frunevetmab, is the first veterinary monoclonal antibody approved by the U.S. Food and Drug Administration.